^
    Apply
    A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China (NCT05009329)
    Phase 1/2
    Jacobio Pharmaceuticals Co., Ltd.
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    07/26/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    glecirasib (JAB-21822)
    A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer (NCT06008288)
    Phase 2
    Jacobio Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    03/12/2024
    Initiation :
    10/27/2023
    Primary completion :
    05/01/2025
    Completion :
    11/01/2025
    KRAS • MSI
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • KRAS G12
    |
    glecirasib (JAB-21822)
    JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation (NCT05002270)
    Phase 1/2
    Jacobio Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    09/07/2023
    Initiation :
    09/03/2021
    Primary completion :
    01/01/2024
    Completion :
    07/01/2025
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • glecirasib (JAB-21822)
    JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation (NCT05194995)
    Phase 1/2
    Jacobio Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    03/10/2023
    Initiation :
    02/17/2022
    Primary completion :
    12/01/2023
    Completion :
    01/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • glecirasib (JAB-21822)
    A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1 (NCT05276726)
    Phase 1/2
    Jacobio Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    09/28/2022
    Initiation :
    08/17/2022
    Primary completion :
    12/01/2023
    Completion :
    02/01/2026
    KRAS • STK11 • KEAP1
    |
    KRAS mutation • KRAS G12C • STK11 mutation • KEAP1 mutation • KRAS G12
    |
    glecirasib (JAB-21822)
    Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation (JAB-21822-1006) (NCT05288205)
    Phase 1/2
    Jacobio Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    06/30/2022
    Initiation :
    04/14/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    glecirasib (JAB-21822) • sitneprotafib (JAB-3312)